These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pharmacoeconomics: an emerging discipline. Letizia C Qual Assur; 1995 Mar; 4(1):68-74. PubMed ID: 8520866 [TBL] [Abstract][Full Text] [Related]
3. Issues in the economic evaluation of treatment for dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Winblad B; Hill S; Beermann B; Post SG; Wimo A Alzheimer Dis Assoc Disord; 1997; 11 Suppl 3():39-45. PubMed ID: 9305515 [No Abstract] [Full Text] [Related]
4. Recommendations for best practices in the treatment of Alzheimer's disease in managed care. Fillit HM; Doody RS; Binaso K; Crooks GM; Ferris SH; Farlow MR; Leifer B; Mills C; Minkoff N; Orland B; Reichman WE; Salloway S Am J Geriatr Pharmacother; 2006; 4 Suppl A():S9-S24; quiz S25-S28. PubMed ID: 17157793 [TBL] [Abstract][Full Text] [Related]
5. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria]. Führlinger S Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765 [TBL] [Abstract][Full Text] [Related]
6. Assessing health economic outcome in Alzheimer's disease clinical trials. Jonsson L J Nutr Health Aging; 2007; 11(4):353-5. PubMed ID: 17653498 [TBL] [Abstract][Full Text] [Related]
11. Pharmacoeconomics. Ahuja J; Gupta M; Gupta AK; Kohli K Natl Med J India; 2004; 17(2):80-3. PubMed ID: 15141600 [TBL] [Abstract][Full Text] [Related]
12. Prevalence, costs, and treatment of Alzheimer's disease and related dementia: a managed care perspective. Rice DP; Fillit HM; Max W; Knopman DS; Lloyd JR; Duttagupta S Am J Manag Care; 2001 Aug; 7(8):809-18. PubMed ID: 11519239 [TBL] [Abstract][Full Text] [Related]
13. New therapeutic approaches to cognitive impairment. Schneider LS J Clin Psychiatry; 1998; 59 Suppl 11():8-13. PubMed ID: 9731544 [TBL] [Abstract][Full Text] [Related]
14. Assessing the societal impact of acetylcholinesterase inhibitor therapies. Winblad B; Wimo A Alzheimer Dis Assoc Disord; 1999 Nov; 13 Suppl 2():S9-19. PubMed ID: 10622674 [TBL] [Abstract][Full Text] [Related]
15. [Rivastigmine: a review of its clinical effectiveness]. Spiegel R Rev Neurol; 2002 Nov 1-15; 35(9):859-69. PubMed ID: 12436385 [TBL] [Abstract][Full Text] [Related]
16. Determinants of costs of care for patients with Alzheimer's disease. Jönsson L; Eriksdotter Jönhagen M; Kilander L; Soininen H; Hallikainen M; Waldemar G; Nygaard H; Andreasen N; Winblad B; Wimo A Int J Geriatr Psychiatry; 2006 May; 21(5):449-59. PubMed ID: 16676288 [TBL] [Abstract][Full Text] [Related]
18. [Health outcomes analysis and its applications]. Carrera-Hueso FJ Rev Med Univ Navarra; 1997; 41(4):237-44. PubMed ID: 10420964 [TBL] [Abstract][Full Text] [Related]
19. Alzheimer's disease: clinical features and pharmacologic management. Franks AS; Rawls WN Am J Manag Care; 1998 Apr; 4(4):595-604; quiz 606-7. PubMed ID: 10179918 [No Abstract] [Full Text] [Related]
20. Pharmacoeconomics: state of the art in 1997. Schulman KA; Linas BP Annu Rev Public Health; 1997; 18():529-48. PubMed ID: 9143730 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]